Biogen (BIIB) operating income was $2.8B in FY2021 (-38% YoY). The tables below show the complete quarterly and annual operating income history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Operating Income
Fiscal Year
Operating Income
YoY
2021
$2.8B
-38%
2020
$4.6B
-35%
2019
$7.0B
+19%
2018
$5.9B
+10%
2017
$5.3B
+3%
2016
$5.2B
+4%
2015
$5.0B
+25%
2014
$4.0B
+58%
2013
$2.5B
+35%
2012
$1.9B
+7%
2011
$1.7B
+32%
2010
$1.3B
+2%
2009
$1.3B
+7%
2008
$1.2B
+56%
2007
$780M
Recent Quarterly Operating Income
Quarter
Operating Income
Q1 2026
$670M
Q4 2025
$592M
Q3 2025
$829M
Q2 2025
$1.1B
Q1 2025
$795M
Q4 2024
$678M
Q3 2024
$722M
Q2 2024
$860M
Q1 2024
$721M
Q4 2023
$605M
Q3 2023
$346M
Q2 2023
$731M
Source: BIIB on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.